ClinicalTrials.gg
CompletedNCT00038948Updated May 14, 2010Results posted

Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

A Phase 3 interventional study of Sirolimus and tacrolimus in Renal Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2010-05-14.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
830
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.

02

Conditions studied

  • Renal Transplantation

Keywords

  • Renal
  • Allograft
  • Recipients
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 13 years.
  • Receiving CsA or tacrolimus from the time of transplantation or within 2 weeks thereafter
  • Patients with a functioning allograft and a Nankivell greater than or equal to 20 mL/min, within 2 weeks before randomization

Exclusion criteria

Exclusion Criteria:

  • -confirmed acute rejection within 12 weeks before randomization, that was determined to require antirejection treatment
  • Patients in whom kidney-pancreas or other multiple organ transplants have been performed
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
830 participants (actual)

Study arms

  • Active comparator
    A

    Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression

    Drug: Sirolimus · Drug: tacrolimus · Drug: Cyclosporine A

  • Active comparator
    B

    Continued calcineurin inhibitor therapy

    Drug: Sirolimus · Drug: tacrolimus · Drug: Cyclosporine A

Interventions

06

What researchers measure

Primary outcomes

  1. Nankivell Glomerular Filtration Rate (GFR)

    Nankivell GFR: patients with baseline GFR of 20.0 to 40.0 mL/min and patients with baseline GFR of greater than 40.0 mL/min. GFR is an index of kidney function. A higher value means better kidney function.

    Time frame: 52 weeks

Secondary outcomes

  1. First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.

    Number of patients who experienced for the first time either biopsy-confirmed acute rejection, graft loss, or death by weeks 52 and 104. Assessed by individual endpoint and as composite endpoint (all combined).

    Time frame: 52 and 104 weeks

07

Results

Posted May 14, 2010

Participant flow

Patients were recruited worldwide from January 2002 to September 2003.

Participant flow — Overall Study
MilestoneSRL Conversion in Stable Renal Transplant RecipientsCNI Continuation in Stable Renal Transplant Recipients
Started555275
Completed386198
Not completed16977
Withdrew: Adverse event13143
Withdrew: Lost to follow-up44
Withdrew: Nonmedical event57
Withdrew: Withdrawal by subject2310
Withdrew: Protocol violation37
Withdrew: Lack of efficacy36

Outcome measures

PrimaryNankivell Glomerular Filtration Rate (GFR)

Nankivell GFR: patients with baseline GFR of 20.0 to 40.0 mL/min and patients with baseline GFR of greater than 40.0 mL/min. GFR is an index of kidney function. A higher value means better kidney function.

Time frame:
52 weeks
Reported as:
Mean · mL/min
Nankivell Glomerular Filtration Rate (GFR)
mL/minSRL Conversion Strata 20.0-40.0 mL/MinCNI Continuation Strata 20.0-40.0 mL/MinSRL Conversion Strata >40.0 mL/MinCNI Continuation Strata >40.0 mL/Min
Nankivell Glomerular Filtration Rate (GFR)24.56 ± 2.4227.24 ± 3.7159.04 ± 0.8957.73 ± 1.1
Statistical analysis
  • SRL Conversion Strata 20.0-40.0 mL/Min vs CNI Continuation Strata 20.0-40.0 mL/Min · ANCOVA · p = 0.575 (Analysis of covariance p-value) · Weighted difference: -2.68 · 95% CI -12.27 to 6.91Data was adjusted for baseline and center.
  • SRL Conversion Strata >40.0 mL/Min vs CNI Continuation Strata >40.0 mL/Min · ANCOVA · p = 0.278 (Analysis of covariance p-value) · Weighted difference: 1.31 · 95% CI -1.06 to 3.69Data was adjusted for baseline and center.
SecondaryFirst Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.

Number of patients who experienced for the first time either biopsy-confirmed acute rejection, graft loss, or death by weeks 52 and 104. Assessed by individual endpoint and as composite endpoint (all combined).

Time frame:
52 and 104 weeks
Reported as:
Number · patients
First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.
patientsSRL Conversion Strata 20.0-40.0 mL/MinCNI Continuation Strata 20.0-40.0 mL/MinSRL Conversion Strata >40.0 mL/MinCNI Continuation Strata >40.0 mL/Min
52 weeks - Acute rejection4083
52 weeks - Graft loss7333
52 weeks - Death3061
52 weeks - Missing0051
104 weeks - Acute rejection51279
104 weeks - Graft loss129128
104 weeks - Death70133
104 weeks - Missing02138
Statistical analysis
  • SRL Conversion Strata 20.0-40.0 mL/Min vs CNI Continuation Strata 20.0-40.0 mL/Min vs SRL Conversion Strata >40.0 mL/Min vs CNI Continuation Strata >40.0 mL/Min · Cochran-Mantel-Haenszel · p = 0.135 (Tests the equality of rates between treatments across strata at 52 weeks.)
  • SRL Conversion Strata 20.0-40.0 mL/Min vs CNI Continuation Strata 20.0-40.0 mL/Min vs SRL Conversion Strata >40.0 mL/Min vs CNI Continuation Strata >40.0 mL/Min · Cochran-Mantel-Haenszel · p = 0.559 (Tests the equality of rates between treatments across strata at 104 weeks.)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SRL Conversion in Stable Renal Transplant Recipients—81/551 (14.7%)545/551 (98.9%)
CNI Continuation in Stable Renal Transplant Recipients—45/273 (16.5%)264/273 (96.7%)
Most frequent serious events
Showing 10 of 275
Most frequent serious events
EventSRL Conversion in Stable Renal Transplant RecipientsCNI Continuation in Stable Renal Transplant Recipients
PneumoniaRespiratory, thoracic and mediastinal disorders57/55111/273
FeverGeneral disorders43/55110/273
InfectionGeneral disorders40/5518/273
Kidney function abnormalRenal and urinary disorders29/55118/273
DiarrheaGastrointestinal disorders36/5513/273
Creatinine increasedMetabolism and nutrition disorders36/5519/273
Urinary tract infectionRenal and urinary disorders33/55112/273
Skin carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/55115/273
GastroenteritisGastrointestinal disorders28/5514/273
AnemiaBlood and lymphatic system disorders21/5513/273
Most frequent other events
Showing 10 of 90
Most frequent other events
EventSRL Conversion in Stable Renal Transplant RecipientsCNI Continuation in Stable Renal Transplant Recipients
HyperlipemiaMetabolism and nutrition disorders317/55183/273
HypercholesteremiaMetabolism and nutrition disorders245/55144/273
DiarrheaGastrointestinal disorders234/55175/273
AnemiaBlood and lymphatic system disorders219/55161/273
Peripheral edemaMetabolism and nutrition disorders190/55151/273
InfectionGeneral disorders177/55171/273
AlbuminuriaRenal and urinary disorders166/55145/273
HypertensionCardiac disorders127/55168/273
Urinary Tract InfectionRenal and urinary disorders127/55158/273
FeverGeneral disorders125/55128/273

Baseline characteristics

Age Continuous
Age Continuous(years)SRL Conversion in Stable Renal Transplant RecipientsCNI Continuation in Stable Renal Transplant RecipientsTotal
Median45.00 (13.20 to 75.10)43.50 (12.80 to 74.00)44.50 (12.80 to 75.10)
Sex: Female, Male
Sex: Female, Male(Participants)SRL Conversion in Stable Renal Transplant RecipientsCNI Continuation in Stable Renal Transplant RecipientsTotal
Female17081251.0
Male385194579.0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Reichen J, Stickel F, Bhattacharya I, Matschke K, Maller E, Korth-Bradley J. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. Eur J Clin Pharmacol. 2012 May;68(5):589-97. doi: 10.1007/s00228-011-1172-7. Epub 2011 Dec 6. PubMed 22143911 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2002
First posted
Jun 7, 2002
Start
Jan 2002
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
May 14, 2010
Last update
May 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00038948
First posted
Jun 7, 2002
Start date
Jan 2002
Primary completion
May 2008
Completion
May 2008
Results posted
May 14, 2010
Last update
May 14, 2010

Study contacts

Medical Monitor, MD
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion